No more rice paddy? New strain that only needs irrigation is adapted to global warming
A cold, dry part of Chile might not sound like the best place to grow rice, a famously thirsty grain that thrives in tropical conditions.
Advertisement
However, a new strain of the world's favourite cereal developed by scientists in the drought-plagued South American country has generated hope that rice can be grown in seemingly inhospitable conditions.
Using an innovative planting technique, Javier Munoz has been trying out the 'Jaspe' strain created by experts at the Agricultural Research Institute's (INIA) rice breeding programme. The INIA is part of the Chilean Ministry of Agriculture.
It is one of several research efforts worldwide to come up with
less resource-hungry crops at a time of increased water scarcity in parts of the world because of global warming.
A sign that reads 'Historical Varieties' is pictured at the INIA experimental rice cultivation site in Chile. Photo: AFP
An aerial view of INIA's experimental rice crops in Chile. Typically grown in wetter, tropical areas, rice cultivation in Chile has been hampered by an unprecedented megadrought, now in its 15th year. Photo: AFP
Using Jaspe in combination with a growing method that requires only intermittent watering cuts the Munoz family's water consumption in half in a country that has for generations cultivated rice in flooded fields, or paddies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RTHK
21-05-2025
- RTHK
Beijing seeking Mars sample return proposals from SARs
Beijing seeking Mars sample return proposals from SARs A model of Tianwen-1's Mars rover is on display at the InnoTech Expo in 2022 in Hong Kong. File photo: NurPhoto/AFP China is seeking payload proposals for its Mars sample return mission and inviting overseas researchers to participate. The China National Space Administration (CNSA) has called on overseas research institutions, including those in Hong Kong and Macau, to submit proposals for developing payloads for the Tianwen-3 mission. The mission, a significant part of China's planetary exploration programme, is scheduled for launch around 2028. The Tianwen-3 spacecraft comprises a lander, an ascent vehicle, a service module, an orbiter and a return module and is equipped with six scientific payloads. The six payloads, namely, the Raman fluorescence spectrometer, ultra-wideband exploration radar, mid-infrared superfine imaging spectrometer, Mars global multicolour camera, descent ENA aurora detector and high-precision vector magnetometer, are all open to overseas researchers, according to a notice released by the CNSA. The CNSA requires that all payload projects be led by a domestic institution, with no more than five entities involved in the joint development of a single payload. Last month, the administration announced that it would offer payload resources for international cooperation, with up to 15 kilogrammes available on the orbiter and five kilogrammes on the service module. The primary scientific objective of the mission is to search for signs of life on Mars. Other areas of exploration include the Martian climate and its evolution, the planet's geology and its internal processes. (Xinhua)
RTHK
17-05-2025
- RTHK
Chinese firm launches first methane-powered rocket
Chinese firm launches first methane-powered rocket Visitors get a closer look at LandSpace's rocket propulsion system at its offices in Beijing. File photo: AFP A new methane-powered rocket developed by China's LandSpace Technology launched six satellites into orbit on Saturday, doubling down on a cheap, cleaner fuel that the private startup hopes will help it develop reusable rockets. The Zhuque-2E Y2 carrier rocket blasted off at 12.12 pm from the Jiuquan Satellite Launch Center in northwest China, marking the fifth flight for the Zhuque-2 series, according to a company statement. Beijing-based LandSpace became the world's first company to launch a methane-liquid oxygen rocket in July 2023, ahead of US rivals such as Elon Musk's SpaceX and Jeff Bezos' Blue Origin. Interest has grown in recent years in launching carrier vehicles fuelled by methane, which is deemed less polluting, safer and cheaper than more commonly used hydrocarbon fuels and a suitable propellant in a reusable rocket. LandSpace has increased the rocket's payload, reflecting increasing demand in China's expanding commercial space industry amid growing competition to form a constellation of satellites as an alternative to Musk's Starlink. Its first successful methane-powered launch did not carry any real satellites, but the second launch in December 2023 successfully sent into orbit three satellites. Reusable rockets, pioneered by SpaceX, have demonstrated that they can lower costs for launch vehicles and space transportation. LandSpace founder and CEO Zhang Changwu has said the company had started developing reusable rockets and expected to conduct a test launch in the second half of 2025. The latest model in its Zhuque-2 series includes technical improvements that will help the company's goal of launching a reusable rocket. Saturday's launch marked the first time LandSpace has deployed a propulsion method that involves chilling both liquid oxygen and methane below their boiling points, boosting thrust. Chinese commercial space firms have rushed into the sector since 2014, when the government allowed private investment in the industry. LandSpace was one of the earliest and best-funded entrants. Founded in 2015, it has secured funding from investors such as venture capital firm HongShan, known at the time as Sequoia Capital China, the investment arm of Chinese property developer Country Garden and the state-backed China SME Development Fund. LandSpace raised 900 million yuan in December from a state-owned fund focused on advanced manufacturing, while in 2020 it raised 1.2 billion yuan, Chinese corporate databases showed. (Reuters)
RTHK
16-05-2025
- RTHK
Sick baby gets first ever gene-editing treatment
Sick baby gets first ever gene-editing treatment A computer illustration of the Crispr-Cas9 genome editing enzyme. File image: AFP An infant in the United States with a rare condition has become history's first patient to be treated with a personalised gene-editing technique that raises hopes for other people with obscure illnesses, doctors said. KJ Muldoon is now nine-and-a-half-months-old. Shortly after birth, he was diagnosed with a rare and serious condition called CPS1 deficiency. It is caused by a mutation in a gene that produces an enzyme key to liver function and prevents people with it from eliminating certain kinds of toxic waste produced by their metabolism. "You Google 'CPS1 deficiency' and it's either fatality rate or liver transplant," the baby's mother, Nicole Muldoon, says in a video released on Thursday by the Children's Hospital of Philadelphia, where the baby was treated. With the prognosis grim, doctors suggested something that had never been done before: a personalised treatment to fix the baby's genome using what amounts to a pair of molecular scissors – the technique called Crispr-Cas9, which earned its creators the Nobel prize for chemistry in 2020. The boy's father said he and his wife faced an impossible decision. "Our child is sick," said Kyle Muldoon. "We either have to get a liver transplant or give him this medicine that's never been given to anybody before, right?" In the end, they agreed to have the child treated with an infusion created just for him to fix his genetic mutation – incorrect DNA letters in the several billion that make up the human genome. "The drug is really designed only for KJ, so the genetic variants that he has are specific to him. It's personalised medicine," said Rebecca Ahrens-Nicklas, a member of the medical team who specialises in paediatric genetics. Once the tailor-made infusion reaches the liver, the molecular scissors contained in it penetrates cells and goes to work editing the boy's flawed gene. The results were promising for other people with genetic conditions, said the medical team, which published their study on Thursday in the New England Journal of Medicine. KJ can now follow a diet richer in proteins that his condition prohibited before and does not need as much medicine as he used to. But he will need to follow up long term to monitor the safety and efficacy of the treatment, the team said. Ahrens-Nicklas said she hoped this achievement will allow the boy to get by with little or no medication some day. "We hope he is the first of many to benefit from a methodology that can be scaled to fit an individual patient's needs," she said. (AFP)
